Regulatory Watch
Mar 2026: NPR covers peptide reclassification (March 26) — mainstream audience discovers peptide market Mar 2026: 29 days post-RFK announcement: FDA has STILL not published reclassification — no Federal Register notice, no updated list Mar 2026: SAFE Drugs Act filed as H.R. 6509 — bipartisan bill would ban RUO sales of compounds identical to FDA-approved drugs Mar 2026: PolitiFact publishes peptide safety fact-check — documents gap between marketing claims and published evidence Mar 2026: Hims & Hers vendor profile added — NYSE-listed telehealth company building peptide manufacturing in California Mar 2026: 30+ clinic websites publishing reclassification articles — all financially conflicted, none independent Mar 2026: BREAKING: Peptide Sciences shuts down operations (March 6) — largest grey-market vendor gone Mar 2026: Finnrick data: Peptide Sciences BPC-157 scored A, but retatrutide scored E with counterfeit flagged across 37 samples Mar 2026: MMM Online: 'Get ready for the peptides gold rush' — pharma trade media covers market explosion Mar 2026: Jay Campbell: 'Federal government has decided RUO peptide manufacturing can no longer sell injectable peptides' Mar 2026: Grips Intelligence: Peptide Sciences was doing $7.4M/month in sales before shutdown — market vacuum now open Mar 2026: All American Peptide owners plead guilty — $3M+ forfeitures. Tailor Made Compounding: $1.79M forfeiture. June 2025: FDA raids Amino Asylum warehouse; website goes offline, operations cease Feb 2025: FDA declares semaglutide shortage resolved — compounding exception ends Sept 2025: FDA issues 50+ warning letters to GLP-1 compounders; DOJ involvement confirmed Nov 2025: Alabama obtains TRO against GLP-1 distributors — first state-level injunctive relief Sept 2023: FDA moves BPC-157, TB-500, and 15 other peptides to Category 2 — compounding prohibited Dec 2024: PCAC votes against allowing compounding of ipamorelin, MK-677, CJC-1295, AOD-9604 Jan 2025: FDA eliminates Category 2/3 system; prohibited substances remain prohibited Feb 2026: STAT News: 35 of 36 BPC-157 studies are animal-only from single lab with undisclosed conflicts 2025: Chinese peptide imports to US double to $328M; online peptide advertising up 678% since 2022 Mar 2026: NPR covers peptide reclassification (March 26) — mainstream audience discovers peptide market Mar 2026: 29 days post-RFK announcement: FDA has STILL not published reclassification — no Federal Register notice, no updated list Mar 2026: SAFE Drugs Act filed as H.R. 6509 — bipartisan bill would ban RUO sales of compounds identical to FDA-approved drugs Mar 2026: PolitiFact publishes peptide safety fact-check — documents gap between marketing claims and published evidence Mar 2026: Hims & Hers vendor profile added — NYSE-listed telehealth company building peptide manufacturing in California Mar 2026: 30+ clinic websites publishing reclassification articles — all financially conflicted, none independent Mar 2026: BREAKING: Peptide Sciences shuts down operations (March 6) — largest grey-market vendor gone Mar 2026: Finnrick data: Peptide Sciences BPC-157 scored A, but retatrutide scored E with counterfeit flagged across 37 samples Mar 2026: MMM Online: 'Get ready for the peptides gold rush' — pharma trade media covers market explosion Mar 2026: Jay Campbell: 'Federal government has decided RUO peptide manufacturing can no longer sell injectable peptides' Mar 2026: Grips Intelligence: Peptide Sciences was doing $7.4M/month in sales before shutdown — market vacuum now open Mar 2026: All American Peptide owners plead guilty — $3M+ forfeitures. Tailor Made Compounding: $1.79M forfeiture. June 2025: FDA raids Amino Asylum warehouse; website goes offline, operations cease Feb 2025: FDA declares semaglutide shortage resolved — compounding exception ends Sept 2025: FDA issues 50+ warning letters to GLP-1 compounders; DOJ involvement confirmed Nov 2025: Alabama obtains TRO against GLP-1 distributors — first state-level injunctive relief Sept 2023: FDA moves BPC-157, TB-500, and 15 other peptides to Category 2 — compounding prohibited Dec 2024: PCAC votes against allowing compounding of ipamorelin, MK-677, CJC-1295, AOD-9604 Jan 2025: FDA eliminates Category 2/3 system; prohibited substances remain prohibited Feb 2026: STAT News: 35 of 36 BPC-157 studies are animal-only from single lab with undisclosed conflicts 2025: Chinese peptide imports to US double to $328M; online peptide advertising up 678% since 2022

Biokey Research

biokeyresearch.com ↗
Founded: Unknown HQ: Unknown Last reviewed: February 20, 2026
F
Overall Grade
Transparency 5/100
Testing 5/100
Pricing 50/100
Reputation 5/100
Compliance 10/100
Publishes COA No
Third-Party Testing No
FDA Warning Letters 0
Product Types unknown

Company Overview

Biokey Research could not be independently verified through any standard business information sources.

What Our Research Found: Nothing

Multiple search variations across all standard verification databases returned zero relevant results:

  • BBB: No listing found
  • FDA databases: No warning letters, no inspection records, no facility registration
  • Trustpilot: No profile
  • Reddit: No mentions in peptide or research chemical communities
  • News archives: No press coverage, positive or negative
  • State business registrations: No verifiable corporate filing identified

The complete absence of any independent digital footprint is itself the most significant finding.

Why This Matters

Legitimate businesses leave traces — even small ones have BBB listings, business registrations, customer reviews, social media presence, or news mentions. A company selling products intended for human consumption (whether labeled “research use” or not) that has zero verifiable independent presence raises fundamental questions about:

  • Business legitimacy: Is this a registered, operational business entity?
  • Product sourcing: Where do their products come from?
  • Quality assurance: Who tests their products, if anyone?
  • Accountability: If something goes wrong, who is responsible?
  • Consumer recourse: Can you dispute charges, request refunds, or file complaints?

Scoring Rationale

We don’t assign F grades lightly. In Biokey Research’s case, the grade reflects not a documented history of problems (like Tailor Made Compounding’s criminal conviction), but rather the complete inability to verify anything about the company at all. We cannot assess what we cannot find.

Transparency: 5/100 — Cannot verify any claims because no independent information exists.

Testing: 5/100 — No evidence of any testing program, no COAs, no named labs.

Reputation: 5/100 — Zero customer feedback from any source, positive or negative.

Compliance: 10/100 — Cannot verify basic business registration or regulatory standing.

Red Flags

  1. Zero verifiable independent information exists about this company
  2. No BBB listing, no Trustpilot, no Reddit mentions, no news coverage
  3. No identifiable founders, leadership, or corporate structure
  4. No evidence of FDA facility registration or inspection
  5. Complete absence of customer reviews from any platform

The Bottom Line

We cannot tell you whether Biokey Research sells good products or bad products, because we cannot verify that they are a real, operational business. The complete absence of any independent footprint — no reviews, no regulatory records, no business registrations, no news mentions — is the information itself. In a market where product quality is already uncertain, purchasing from a vendor with zero verifiable identity adds an additional, unnecessary layer of risk.